A systemwide, multipronged pain management and opioid reduction program can significantly reduce opioid discharge prescriptions written for more than five days.
The FDA has approved Anjeso (meloxicam injection; Baudax Bio) for the management of moderate to severe pain, alone or in combination with NSAIDs in adult patients.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
Production and distribution of Excedrin Extra Strength and Excedrin Migraine products have been temporarily stopped.
A ready-to-use formulation of Caldolor (ibuprofen injection) has been made available by Cumberland Pharmaceuticals.
Regional anesthesia may aid pain management if used soon after traumatic injury of the extremities.
The application includes data from two phase 3 clinical trials in patients following bunionectomy and abdominoplasty surgeries.
If approved, the Company expects that the drug would be classified as a Schedule II controlled substance.
Higher serum testosterone levels were associated with less WOMAC pain in the operated knee in both men and women, and less WOMAC disability in women.
Though gastroenterologists are prescribing fewer opioids for Medicare patients, they should also prescribe more neuromodulators because there is more high-quality evidence supporting their efficacy for conditions causing chronic abdominal pain conditions.